Parliamentary Committees and Public Enquiries
Brexit negotiators urged to prioritise patient safety
The Health and Social Care Committee urges UK and EU negotiators to prioritise patient safety in next round of Brexit negotiations in its report into Brexit: medicines, medical devices and substances of human origin.
- Read the report summary
- Read the conclusions and recommendations
- Read the full report: Brexit – medicines, medical devices and substances of human origin
Negotiators on both sides must heed the call of industry and patient groups in securing the closest possible regulatory alignment in the next round of Brexit talks.
Chair of the Committee, Dr Sarah Wollaston MP, says:
"In order to minimise harm to their citizens, both the UK and the EU-27 should look to secure the closest possible regulatory alignment in the next round of the Brexit negotiations. Failure to do so would signal a triumph of ideology over the best interests of patients."
The Committee welcomes the Government’s stated intention to maintain regulatory alignment with the European Medicines Agency (EMA). The entire supply chain of pharmaceuticals, from research and development through to the product being available on a pharmacy shelf, will be adversely affected by regulatory divergence and seriously so in the event of a 'no deal' Brexit
However, the European Council has stated that preserving the integrity of the Single Market excludes participation based on a sector-by-sector approach. Any provisions for continued co-operation between the EU and the UK in the life sciences are dependent on similar agreements across the whole of the negotiations. We believe it is not just prudent, but essential, that scrutiny is undertaken of the Department of Health and Social Care’s contingency planning for a ‘no deal’ situation.
Clinical Trials and Research and Development
For the benefit of patients, particularly with rare conditions, on both sides of the Channel, it is vital that the UK life sciences sector is able to continue to participate in Europe-wide clinical trials. If the UK does not adopt the new clinical trials regulations and is unable to access the EU infrastructure developed within the EU to underpin them, difficulties for patients and the life science industry could emerge.
The UK should seek to continue to be a member of EU Research and Development (R&D) funding and research mechanisms such as Horizon 2020 after leaving the EU, if possible on the same terms as it currently enjoys.
The UK should also seek mutual recognition of pharmacovigilance mechanisms by the MHRA and the EMA as a priority in the next round of negotiations, as the failure to do so could affect patient safety both in the UK and the EU. It is also in the best interests of patients for the UK to continue membership of all of the major EU pharmacovigilance systems and databases, including the European Database on Medical Devices (EUDAMED) and Eudravigilance.
Trade, customs and supply chains
We support the case for free and frictionless trade with the EU. The Government should assess the impact of the loss of parallel imports. We also recommend that the Government undertake further contingency planning on the impact on the supply chain of a failure to achieve free and frictionless trade in pharmaceutical products.
Latest News from
Parliamentary Committees and Public Enquiries
Treasury Committee comments on responses to Greensill inquiry correspondence07/05/2021 13:15:00
The Committee has received responses to the Chair’s letters. It is unable to publish these letters during Prorogation, but will do so when Parliament returns next week, ahead of the evidence session with Lex Greensill on Tuesday.
Committee receives Government response to key report on procedure after coronavirus restrictions07/05/2021 09:15:00
The Procedure Committee publishes the Government’s response to its detailed report setting out a procedural roadmap for coming out of the current lockdown.
Change the law now to ensure end to blanket bans on care home visits, urges Joint Committee05/05/2021 11:15:00
The Joint Committee on Human Rights has prepared a draft statutory instrument to lay before Parliament to secure legal protection for care home residents deprived of family visits, and therefore, their human rights.
Supply chain for battery electric vehicles inquiry launched04/05/2021 15:05:00
In the latest stage of its Technological Innovation and Climate Change inquiry, the Environmental Audit Committee (EAC) announces that it is to look at the supply chain for battery electric vehicles.
Privileges Committee publish key report on select committee powers03/05/2021 10:20:00
The Committee of Privileges publishes a key report on select committee powers, setting out preliminary proposals to ensure the committee powers to call for persons, papers and records can be enforced and that witnesses before committees are treated fairly.
MPs urge Government to level playing field for meat and seafood exporters30/04/2021 13:05:00
The Government must take a 'pragmatic' approach in discussions with the EU to reduce 'considerable' non-tariff barriers—including red tape and checks— that the new GB-EU trading environment has created for British companies.
European Statutory Instruments Committee publishes twenty-fourth report29/04/2021 16:10:00
Following the Committee's meeting on Tuesday 27 April, its twenty-fourth report of Session 2019-21 has been published.
Mineworkers’ pensions - Government should fix ‘historic injustice’ felt by Scheme members29/04/2021 11:15:00
The Government should review the surplus sharing arrangements in the Mineworkers’ Pension Scheme to ensure they are fair and deliver a better outcome for pensioners, say the Business, Energy and Industrial Strategy (BEIS) Committee.